Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab and Dalpiciclib in Resectable ESCC
NCT06225921Phase 1Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of adebrelimab and dalpiciclib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Safety of combination adebrelimab and dalpiciclib at 15 weeks. Started Dec 2023; status: recruiting.
02
Drugs
adebrelimabdalpiciclib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06225921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06225921.